| About the author: |
Budnik T.V., Kvashnina L.V. |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
The purpose of the study was to establish the effectiveness of combined phyto-citrate compound in the treatment and prevention of recurrent urinary tract infections in children with saline dysmetabolism in the comparison groups. The study involved 33 children aged 6 to 18 years, patients with recurrent urinary tract infections in the acute exacerbation of the disease. According to the duration of combined phyto-citrate compound administration, children were divided into 2 groups: I (n=17) – received the drug in complex therapy of urinary tract infections for 1 month, II (n=16) – also received phyto-citrate compound in complex therapy for 1 month, but continued to take it to prevent urinary tract infections for the next 2 months in an intermittent mode for 10 days. The results of the study proved phyto-citrate effectiveness in the complex therapy of recurrent urinary tract infections in children on the background of saline dysmetabolism. Administration of this drug led to normalization of saline transport indicators in 82% (27/33) of patients (p<0.05) after the 1st month of treatment and reduced the risk of reinfection by 18 times: OR = 4.25±0.65 with 95% CI [1.18; 15.3] – before treatment and OR = 0.235±0.65 [0.066; 0.846] – after the first month of treatment (p<0.001). Prolonged intermittent administration of the drug for the next 2 months reduced the risk of recurrent episodes of urinary tract infection by 3.5 times: OR = 1.88±0.9 [0.302; 11.73] – in case of choosing a 1-month course of therapy; and OR= 0.53±0.83 [0.085; 3.3], p<0.05 – as a result of preventive use of the combined phyto-citrate. |
| Tags |
recurrent urinary tract infection, children, mineral dysmetabolism, combined phyto-citrate compound |
| Bibliography |
- Beiraghdar F, Panahi Y, Einollahi B, Moharamzad Y, Nemati E, Amirsalari S. Predisposing factors for renal scarring in children with urinary tract infection. Saudi J Kidney Dis Transplant. 2012; 23(3):532–37.
- Bland M. An introduction to medical statistics. Oxford University Press, 4th edition. 2015. 464 pp. ISBN 978-0-19-958992-0.
- Bleidorn J, Hummers-Pradier E, Schmiemann G, Wiese B, Gagyor I. Recurrent urinary tract infections and complications after symptomatic versus antibiotic treatment: follow-up of a randomised controlled trial. Ger Med Sci. 2016; 14.
- Conover MS, Hadjifrangiskou M, Palermo JJ, Hibbing ME, Dodson KW, Hultgren SJ. Metabolic requirements of Escherichia coli in intracellular bacterial communities during urinary tract infection pathogenesis. mBio. 2016; 7(2):1–13. https://doi.org/10.1128/mBio.00104-16
- Dawson CH, Thomson CRV. Kidney stone disease: pathophysiology, investigation and medical treatment. Journal of Clinical Medicine. 2012; 12(5):467–471. doi: 10.7861/clinmedicine.12-5-467.
- Gondim R., Azevedo R., Braga A.A.N.M., Veiga M.L., Barroso UJr. Risk factors for urinary tract infection in children with urinary urgency. Int. Braz J Urol. 2018; 44(2):378–383. doi: 10.1590/S1677-5538.
- Niroomand H, Ziaee A, Ziaee K, Gheissari A. Evaluating the effectiveness of adding magnesium chloride to conventional protocol of citrate alkali therapy on kidney stone size. Adv Biomed Res. 2016; 5:168.
- Ratkalkar VN, Kleinman JG. Mechanisms of stone formation. Clinical Reviews in Bone and Mineral Metabolism. 2011; 9(3-4):187–197. doi: 10.1007/s12018-011-9104-8.
- Sakhaee K. Epidemiology and clinical pathophysiology of uric acid kidney stones. Journal Nephrology. 2014 Jun; 27(3):241–5. doi: 10.1007/s40620-013-0034-z
- Siener R, Bangen U, Sidhu H. The role of Oxalobacter formigenes colonization in calcium oxalate stone disease. Kidney International. 2013 Jun; 83(6):1144–9. doi: 10.1038/ki.2013.104.
- Skolarikos A, Straub M, Knoll T, Sarica K, Seitz C, Petrˇı´k A, Tu¨rk C. Metabolic Evaluation and Recurrence Prevention for Urinary Stone Patients: EAU Guidelines. European urology.2015; 67:750–763.
- Straub M, Strohmaier WL, Berg W. Diagnosis and metaphylaxis of stone disease. Consensus concept of the National Working Committee on Stone Disease for the upcoming German Urolithiasis Guideline. World J. Urol. 2015; 23(5):309-323.
- Viswanathan P, Rimer JD, Kolbach AM, Ward MD, Kleinman JG, Wesson JA. Calcium oxalate monohydrate aggregation induced by aggregation of desialylated Tamm-Horsfall protein. Urological Research. 2011; 39(4):269–282. doi: 10.1007/s00240-010-0353-7.
- Wiederkehr MR, Orson WM. Uric Acid Nephrolithiasis: A Systemic Metabolic Disorder. Clin Rev Bone Miner Metab. 2011; 9(3-4):207–217. doi: 10.1007/s12018-011-9106-6
- Xu H, Zisman AL, Coe FL, Worcester EM. Kidney stones: an update on current pharmacological management and future directions. Expert Opinion on Pharmacotherapy. 2013; 14(4):435–447. doi: 10.1517/14656566.2013.775250.
|
| Publication of the article |
«World of Medicine and Biology» №3(73), 2020 year, 016-021 pages, index UDK 616.61-008.9-06:616.391-085.326-053.2 |
| DOI |
10.26724/2079-8334-2020-3-73-16-21 |
